Review



apc vio770 anti cd8a rea601  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Miltenyi Biotec apc vio770 anti cd8a rea601
    Apc Vio770 Anti Cd8a Rea601, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 106 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8a+apc+vio770/CD8a+Antibody%2C+anti-mouse%2C+REAfinity/pmc12461889-34-0-5
    Average 94 stars, based on 106 article reviews
    apc vio770 anti cd8a rea601 - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    Staining:

    Article Title: Autologous HIV-specific T cell therapy targeting conserved epitopes is well-tolerated in six adults with HIV: an open-label, single-arm phase 1 study
    Article Snippet: The cells were pelleted, washed in PBS, and resuspended with Fc receptor (FcR) blocking solution (Cat: 422302, Biolegend) in PBS for 10 min to increase specificity of antibody staining. .. Antibodies used in panels for cell surface staining differed between the GMP and non-GMP laboratories, and were combinations of the following: CD3 PE-Cy7 (Cat: 317334, Biolegend), CD3 PerCP-Vio700 (Cat: 130-113-141, Miltenyi), CD3 BV785 (Cat: 317330, Biolegend), CD4 BV605 (Cat: 317438, Biolegend), CD4 PE Vio770 (Cat: 130-113-227, Miltenyi), CD8a BV421 (Cat: 301036, Biolegend), CD8a APC Vio770 (Cat: 130-110-681, Miltenyi), CCR7 Alexa Fluor 700 (Cat: 353244, Biolegend), CCR7 FITC (Cat: 130-120-468, Miltenyi), CD45RO PE-Dazzle 594 (Cat: 304248, Biolegend), CD45RO PE (Cat: 130-113-559, Miltenyi), CD19 FITC (Cat: 130-113-645, Miltenyi), CD14 VioBlue (Cat: 130-110-524, Miltenyi), CD16 PE (Cat: 130-113-393, Miltenyi), CD56 BV650 (Cat: 318344, Biolegend), CD56 PE (Cat: 130-113-312, Miltenyi), TCRγδ APC-Fire 750 (Cat: 331228, Biolegend), TCRγδ (Cat: 130-113-512, Miltenyi), TCRαβ PerCP/Cyanine5.5 (Cat: 306724, Biolegend), TCRαβ FITC (Cat: 130-113-538, Miltenyi), CD160 PE-Cy7 (Cat: 341212, Biolegend), CTLA4 PE-Dazzle 594 (Cat: 369616, Biolegend), LAG3 PE (Cat: 369306, Biolegend), PD-1 FITC (Cat: 329904, Biolegend), TIM3 BV650 (Cat: 345028, Biolegend), CD107a PE-Cy7 (Cat: 328618, Biolegend), CD45 APC (Cat: 130-110-633, Miltenyi), CD83 PE (Cat: 130-110-503, Miltenyi), CD62 VioBlue (Cat: 130-113-622, Miltenyi), HLA-DR FITC (Cat: 30-111-788, Miltenyi), and CD95 APC (Cat: 558814, BD Biosciences). .. Following incubation with surface stain antibodies, cells were washed 2 times with PBS and resuspended in 100 uL of 4% cytofix/cytoperm (Cat: 554714, BD Biosciences) solution for 15 min at RT in the dark.

    Article Title: Sepsis inhibits tumor growth in mice with cancer through Toll-like receptor 4-associated enhanced Natural Killer cell activity
    Article Snippet: Red blood cells were removed using BD Pharm LyseTM lysis buffer and cells were enumerated with Accuri C6 before staining. .. Cell-surface staining and flow cytometry The following anti-mouse antibodies were used for FACS staining: CD45-AF700 (30F11, BioLegend), CD3ε-PerCP-Vio700 (145-2C11, Miltenyi Biotec), NK1.1-BV421 (PK136, BioLegend), CD8a-APC-Vio770 (53–6.7,Miltenyi Biotec), CD4BV785 (GK1.5, BioLegend), CD11c-PeCy7 (HL3, BD Biosciences), Ly6G-APC (1A8, BD Biosciences), Ly6C-BV421 (AL-21, BD Biosciences), Tγ/δ-PE (GL3, BD Biosciences), CD19-FITC (1D3, BD Biosciences), CD11b-BV650 (M1/70, BioLegend), CD11b-FITC (M1/70.15.11.5, Miltenyi Biotec), F4/80-PE (REA126, Miltenyi Biotec), CD27-PE-Vio770 (REA499, Miltenyi Biotec), NKG2D-FITC (C7, BioLegend), CD25-APC (PC61, BioLegend), CD107a-BV711 (1D4B, BD Biosciences), IFNγ-PE (XMG1.2, BioLegend), Perforin-APC (S16009A, BioLegend), Granzyme B-FITC (GB11, BioLegend), H-2-FITC (M1/42, BioLegend) and Tlr4 (SA15-21, BioLegend) and their control isotype rat IgG2aκ (BioLegend). .. Cells suspensions were first incubated with Fc-blocker antiCD16/32 antibody (Miltenyi Biotech).

    Article Title: Sepsis inhibits tumor growth in mice with cancer through Toll-like receptor 4-associated enhanced Natural Killer cell activity
    Article Snippet: Red blood cells were removed using BD Pharm Lyse TM lysis buffer and cells were enumerated with Accuri C6 before staining. .. Cell-surface staining and flow cytometry The following anti-mouse antibodies were used for FACS staining: CD45-AF700 (30F11, BioLegend), CD3ε-PerCP-Vio700 (145-2C11, Miltenyi Biotec), NK1.1-BV421 (PK136, BioLegend), CD8a-APC-Vio770 (53–6.7, Miltenyi Biotec), CD4-BV785 (GK1.5, BioLegend), CD11c-PeCy7 (HL3, BD Biosciences), Ly6G-APC (1A8, BD Biosciences), Ly6C-BV421 (AL-21, BD Biosciences), Tγ/δ-PE (GL3, BD Biosciences), CD19-FITC (1D3, BD Biosciences), CD11b-BV650 (M1/70, BioLegend), CD11b-FITC (M1/70.15.11.5, Miltenyi Biotec), F4/80-PE (REA126, Miltenyi Biotec), CD27-PE-Vio770 (REA499, Miltenyi Biotec), NKG2D-FITC (C7, BioLegend), CD25-APC (PC61, BioLegend), CD107a-BV711 (1D4B, BD Biosciences), IFNγ-PE (XMG1.2, BioLegend), Perforin-APC (S16009A, BioLegend), Granzyme B-FITC (GB11, BioLegend), H-2-FITC (M1/42, BioLegend) and Tlr4 (SA15-21, BioLegend) and their control isotype rat IgG2aκ (BioLegend). .. Cells suspensions were first incubated with Fc-blocker anti-CD16/32 antibody (Miltenyi Biotech).

    Article Title: Sepsis inhibits tumor growth in mice with cancer through Toll-like receptor 4-associated enhanced Natural Killer cell activity
    Article Snippet: Red blood cells were removed using BD Pharm Lyse TM lysis buffer and cells were enumerated with Accuri C6 before staining. .. The following anti-mouse antibodies were used for FACS staining: CD45-AF700 (30F11, BioLegend), CD3ε-PerCP-Vio700 (145-2C11, Miltenyi Biotec), NK1.1-BV421 (PK136, BioLegend), CD8a-APC-Vio770 (53–6.7, Miltenyi Biotec), CD4-BV785 (GK1.5, BioLegend), CD11c-PeCy7 (HL3, BD Biosciences), Ly6G-APC (1A8, BD Biosciences), Ly6C-BV421 (AL-21, BD Biosciences), Tγ/δ-PE (GL3, BD Biosciences), CD19-FITC (1D3, BD Biosciences), CD11b-BV650 (M1/70, BioLegend), CD11b-FITC (M1/70.15.11.5, Miltenyi Biotec), F4/80-PE (REA126, Miltenyi Biotec), CD27-PE-Vio770 (REA499, Miltenyi Biotec), NKG2D-FITC (C7, BioLegend), CD25-APC (PC61, BioLegend), CD107a-BV711 (1D4B, BD Biosciences), IFNγ-PE (XMG1.2, BioLegend), Perforin-APC (S16009A, BioLegend), Granzyme B-FITC (GB11, BioLegend), H-2-FITC (M1/42, BioLegend) and Tlr4 (SA15-21, BioLegend) and their control isotype rat IgG2aκ (BioLegend). .. Cells suspensions were first incubated with Fc-blocker anti-CD16/32 antibody (Miltenyi Biotech).

    Flow Cytometry:

    Article Title: Sepsis inhibits tumor growth in mice with cancer through Toll-like receptor 4-associated enhanced Natural Killer cell activity
    Article Snippet: Red blood cells were removed using BD Pharm LyseTM lysis buffer and cells were enumerated with Accuri C6 before staining. .. Cell-surface staining and flow cytometry The following anti-mouse antibodies were used for FACS staining: CD45-AF700 (30F11, BioLegend), CD3ε-PerCP-Vio700 (145-2C11, Miltenyi Biotec), NK1.1-BV421 (PK136, BioLegend), CD8a-APC-Vio770 (53–6.7,Miltenyi Biotec), CD4BV785 (GK1.5, BioLegend), CD11c-PeCy7 (HL3, BD Biosciences), Ly6G-APC (1A8, BD Biosciences), Ly6C-BV421 (AL-21, BD Biosciences), Tγ/δ-PE (GL3, BD Biosciences), CD19-FITC (1D3, BD Biosciences), CD11b-BV650 (M1/70, BioLegend), CD11b-FITC (M1/70.15.11.5, Miltenyi Biotec), F4/80-PE (REA126, Miltenyi Biotec), CD27-PE-Vio770 (REA499, Miltenyi Biotec), NKG2D-FITC (C7, BioLegend), CD25-APC (PC61, BioLegend), CD107a-BV711 (1D4B, BD Biosciences), IFNγ-PE (XMG1.2, BioLegend), Perforin-APC (S16009A, BioLegend), Granzyme B-FITC (GB11, BioLegend), H-2-FITC (M1/42, BioLegend) and Tlr4 (SA15-21, BioLegend) and their control isotype rat IgG2aκ (BioLegend). .. Cells suspensions were first incubated with Fc-blocker antiCD16/32 antibody (Miltenyi Biotech).

    Article Title: Sepsis inhibits tumor growth in mice with cancer through Toll-like receptor 4-associated enhanced Natural Killer cell activity
    Article Snippet: Red blood cells were removed using BD Pharm Lyse TM lysis buffer and cells were enumerated with Accuri C6 before staining. .. Cell-surface staining and flow cytometry The following anti-mouse antibodies were used for FACS staining: CD45-AF700 (30F11, BioLegend), CD3ε-PerCP-Vio700 (145-2C11, Miltenyi Biotec), NK1.1-BV421 (PK136, BioLegend), CD8a-APC-Vio770 (53–6.7, Miltenyi Biotec), CD4-BV785 (GK1.5, BioLegend), CD11c-PeCy7 (HL3, BD Biosciences), Ly6G-APC (1A8, BD Biosciences), Ly6C-BV421 (AL-21, BD Biosciences), Tγ/δ-PE (GL3, BD Biosciences), CD19-FITC (1D3, BD Biosciences), CD11b-BV650 (M1/70, BioLegend), CD11b-FITC (M1/70.15.11.5, Miltenyi Biotec), F4/80-PE (REA126, Miltenyi Biotec), CD27-PE-Vio770 (REA499, Miltenyi Biotec), NKG2D-FITC (C7, BioLegend), CD25-APC (PC61, BioLegend), CD107a-BV711 (1D4B, BD Biosciences), IFNγ-PE (XMG1.2, BioLegend), Perforin-APC (S16009A, BioLegend), Granzyme B-FITC (GB11, BioLegend), H-2-FITC (M1/42, BioLegend) and Tlr4 (SA15-21, BioLegend) and their control isotype rat IgG2aκ (BioLegend). .. Cells suspensions were first incubated with Fc-blocker anti-CD16/32 antibody (Miltenyi Biotech).

    FACS:

    Article Title: Sepsis inhibits tumor growth in mice with cancer through Toll-like receptor 4-associated enhanced Natural Killer cell activity
    Article Snippet: Red blood cells were removed using BD Pharm LyseTM lysis buffer and cells were enumerated with Accuri C6 before staining. .. Cell-surface staining and flow cytometry The following anti-mouse antibodies were used for FACS staining: CD45-AF700 (30F11, BioLegend), CD3ε-PerCP-Vio700 (145-2C11, Miltenyi Biotec), NK1.1-BV421 (PK136, BioLegend), CD8a-APC-Vio770 (53–6.7,Miltenyi Biotec), CD4BV785 (GK1.5, BioLegend), CD11c-PeCy7 (HL3, BD Biosciences), Ly6G-APC (1A8, BD Biosciences), Ly6C-BV421 (AL-21, BD Biosciences), Tγ/δ-PE (GL3, BD Biosciences), CD19-FITC (1D3, BD Biosciences), CD11b-BV650 (M1/70, BioLegend), CD11b-FITC (M1/70.15.11.5, Miltenyi Biotec), F4/80-PE (REA126, Miltenyi Biotec), CD27-PE-Vio770 (REA499, Miltenyi Biotec), NKG2D-FITC (C7, BioLegend), CD25-APC (PC61, BioLegend), CD107a-BV711 (1D4B, BD Biosciences), IFNγ-PE (XMG1.2, BioLegend), Perforin-APC (S16009A, BioLegend), Granzyme B-FITC (GB11, BioLegend), H-2-FITC (M1/42, BioLegend) and Tlr4 (SA15-21, BioLegend) and their control isotype rat IgG2aκ (BioLegend). .. Cells suspensions were first incubated with Fc-blocker antiCD16/32 antibody (Miltenyi Biotech).

    Article Title: Sepsis inhibits tumor growth in mice with cancer through Toll-like receptor 4-associated enhanced Natural Killer cell activity
    Article Snippet: Red blood cells were removed using BD Pharm Lyse TM lysis buffer and cells were enumerated with Accuri C6 before staining. .. Cell-surface staining and flow cytometry The following anti-mouse antibodies were used for FACS staining: CD45-AF700 (30F11, BioLegend), CD3ε-PerCP-Vio700 (145-2C11, Miltenyi Biotec), NK1.1-BV421 (PK136, BioLegend), CD8a-APC-Vio770 (53–6.7, Miltenyi Biotec), CD4-BV785 (GK1.5, BioLegend), CD11c-PeCy7 (HL3, BD Biosciences), Ly6G-APC (1A8, BD Biosciences), Ly6C-BV421 (AL-21, BD Biosciences), Tγ/δ-PE (GL3, BD Biosciences), CD19-FITC (1D3, BD Biosciences), CD11b-BV650 (M1/70, BioLegend), CD11b-FITC (M1/70.15.11.5, Miltenyi Biotec), F4/80-PE (REA126, Miltenyi Biotec), CD27-PE-Vio770 (REA499, Miltenyi Biotec), NKG2D-FITC (C7, BioLegend), CD25-APC (PC61, BioLegend), CD107a-BV711 (1D4B, BD Biosciences), IFNγ-PE (XMG1.2, BioLegend), Perforin-APC (S16009A, BioLegend), Granzyme B-FITC (GB11, BioLegend), H-2-FITC (M1/42, BioLegend) and Tlr4 (SA15-21, BioLegend) and their control isotype rat IgG2aκ (BioLegend). .. Cells suspensions were first incubated with Fc-blocker anti-CD16/32 antibody (Miltenyi Biotech).

    Article Title: Sepsis inhibits tumor growth in mice with cancer through Toll-like receptor 4-associated enhanced Natural Killer cell activity
    Article Snippet: Red blood cells were removed using BD Pharm Lyse TM lysis buffer and cells were enumerated with Accuri C6 before staining. .. The following anti-mouse antibodies were used for FACS staining: CD45-AF700 (30F11, BioLegend), CD3ε-PerCP-Vio700 (145-2C11, Miltenyi Biotec), NK1.1-BV421 (PK136, BioLegend), CD8a-APC-Vio770 (53–6.7, Miltenyi Biotec), CD4-BV785 (GK1.5, BioLegend), CD11c-PeCy7 (HL3, BD Biosciences), Ly6G-APC (1A8, BD Biosciences), Ly6C-BV421 (AL-21, BD Biosciences), Tγ/δ-PE (GL3, BD Biosciences), CD19-FITC (1D3, BD Biosciences), CD11b-BV650 (M1/70, BioLegend), CD11b-FITC (M1/70.15.11.5, Miltenyi Biotec), F4/80-PE (REA126, Miltenyi Biotec), CD27-PE-Vio770 (REA499, Miltenyi Biotec), NKG2D-FITC (C7, BioLegend), CD25-APC (PC61, BioLegend), CD107a-BV711 (1D4B, BD Biosciences), IFNγ-PE (XMG1.2, BioLegend), Perforin-APC (S16009A, BioLegend), Granzyme B-FITC (GB11, BioLegend), H-2-FITC (M1/42, BioLegend) and Tlr4 (SA15-21, BioLegend) and their control isotype rat IgG2aκ (BioLegend). .. Cells suspensions were first incubated with Fc-blocker anti-CD16/32 antibody (Miltenyi Biotech).

    Control:

    Article Title: Sepsis inhibits tumor growth in mice with cancer through Toll-like receptor 4-associated enhanced Natural Killer cell activity
    Article Snippet: Red blood cells were removed using BD Pharm LyseTM lysis buffer and cells were enumerated with Accuri C6 before staining. .. Cell-surface staining and flow cytometry The following anti-mouse antibodies were used for FACS staining: CD45-AF700 (30F11, BioLegend), CD3ε-PerCP-Vio700 (145-2C11, Miltenyi Biotec), NK1.1-BV421 (PK136, BioLegend), CD8a-APC-Vio770 (53–6.7,Miltenyi Biotec), CD4BV785 (GK1.5, BioLegend), CD11c-PeCy7 (HL3, BD Biosciences), Ly6G-APC (1A8, BD Biosciences), Ly6C-BV421 (AL-21, BD Biosciences), Tγ/δ-PE (GL3, BD Biosciences), CD19-FITC (1D3, BD Biosciences), CD11b-BV650 (M1/70, BioLegend), CD11b-FITC (M1/70.15.11.5, Miltenyi Biotec), F4/80-PE (REA126, Miltenyi Biotec), CD27-PE-Vio770 (REA499, Miltenyi Biotec), NKG2D-FITC (C7, BioLegend), CD25-APC (PC61, BioLegend), CD107a-BV711 (1D4B, BD Biosciences), IFNγ-PE (XMG1.2, BioLegend), Perforin-APC (S16009A, BioLegend), Granzyme B-FITC (GB11, BioLegend), H-2-FITC (M1/42, BioLegend) and Tlr4 (SA15-21, BioLegend) and their control isotype rat IgG2aκ (BioLegend). .. Cells suspensions were first incubated with Fc-blocker antiCD16/32 antibody (Miltenyi Biotech).

    Article Title: Sepsis inhibits tumor growth in mice with cancer through Toll-like receptor 4-associated enhanced Natural Killer cell activity
    Article Snippet: Red blood cells were removed using BD Pharm Lyse TM lysis buffer and cells were enumerated with Accuri C6 before staining. .. Cell-surface staining and flow cytometry The following anti-mouse antibodies were used for FACS staining: CD45-AF700 (30F11, BioLegend), CD3ε-PerCP-Vio700 (145-2C11, Miltenyi Biotec), NK1.1-BV421 (PK136, BioLegend), CD8a-APC-Vio770 (53–6.7, Miltenyi Biotec), CD4-BV785 (GK1.5, BioLegend), CD11c-PeCy7 (HL3, BD Biosciences), Ly6G-APC (1A8, BD Biosciences), Ly6C-BV421 (AL-21, BD Biosciences), Tγ/δ-PE (GL3, BD Biosciences), CD19-FITC (1D3, BD Biosciences), CD11b-BV650 (M1/70, BioLegend), CD11b-FITC (M1/70.15.11.5, Miltenyi Biotec), F4/80-PE (REA126, Miltenyi Biotec), CD27-PE-Vio770 (REA499, Miltenyi Biotec), NKG2D-FITC (C7, BioLegend), CD25-APC (PC61, BioLegend), CD107a-BV711 (1D4B, BD Biosciences), IFNγ-PE (XMG1.2, BioLegend), Perforin-APC (S16009A, BioLegend), Granzyme B-FITC (GB11, BioLegend), H-2-FITC (M1/42, BioLegend) and Tlr4 (SA15-21, BioLegend) and their control isotype rat IgG2aκ (BioLegend). .. Cells suspensions were first incubated with Fc-blocker anti-CD16/32 antibody (Miltenyi Biotech).

    Article Title: Sepsis inhibits tumor growth in mice with cancer through Toll-like receptor 4-associated enhanced Natural Killer cell activity
    Article Snippet: Red blood cells were removed using BD Pharm Lyse TM lysis buffer and cells were enumerated with Accuri C6 before staining. .. The following anti-mouse antibodies were used for FACS staining: CD45-AF700 (30F11, BioLegend), CD3ε-PerCP-Vio700 (145-2C11, Miltenyi Biotec), NK1.1-BV421 (PK136, BioLegend), CD8a-APC-Vio770 (53–6.7, Miltenyi Biotec), CD4-BV785 (GK1.5, BioLegend), CD11c-PeCy7 (HL3, BD Biosciences), Ly6G-APC (1A8, BD Biosciences), Ly6C-BV421 (AL-21, BD Biosciences), Tγ/δ-PE (GL3, BD Biosciences), CD19-FITC (1D3, BD Biosciences), CD11b-BV650 (M1/70, BioLegend), CD11b-FITC (M1/70.15.11.5, Miltenyi Biotec), F4/80-PE (REA126, Miltenyi Biotec), CD27-PE-Vio770 (REA499, Miltenyi Biotec), NKG2D-FITC (C7, BioLegend), CD25-APC (PC61, BioLegend), CD107a-BV711 (1D4B, BD Biosciences), IFNγ-PE (XMG1.2, BioLegend), Perforin-APC (S16009A, BioLegend), Granzyme B-FITC (GB11, BioLegend), H-2-FITC (M1/42, BioLegend) and Tlr4 (SA15-21, BioLegend) and their control isotype rat IgG2aκ (BioLegend). .. Cells suspensions were first incubated with Fc-blocker anti-CD16/32 antibody (Miltenyi Biotech).



    Similar Products

    apc vio770 anti cd8a rea601  (Miltenyi Biotec)
    94
    Miltenyi Biotec apc vio770 anti cd8a rea601
    Apc Vio770 Anti Cd8a Rea601, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8a+apc+vio770/CD8a+Antibody%2C+anti-mouse%2C+REAfinity/pmc12461889-34-0-5
    Average 94 stars, based on 1 article reviews
    apc vio770 anti cd8a rea601 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    apc vio770 anti cd8a  (Miltenyi Biotec)
    95
    Miltenyi Biotec apc vio770 anti cd8a
    Apc Vio770 Anti Cd8a, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8a+apc+vio770/CD8a+Antibody%2C+anti-mouse%2C+APC-Vio+770/pmc10861893__pnas__2309243121__sapp-7-54-63
    Average 95 stars, based on 1 article reviews
    apc vio770 anti cd8a - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    cd8a apc vio770  (Miltenyi Biotec)
    95
    Miltenyi Biotec cd8a apc vio770
    a HST-NEET products ( n = 6) exhibited variable antigen-specific IFN-γ responses against HIV Gag, Pol, Nef, and conserved epitope targets in the Gag/Pol Mos1 and Mos2 peptide mixes. RESIST-004 HST-NEET numbers after treatment-related studies were insufficient to test Gag/Pol Mos1 and Mos2 specificity. Positive ELISpot results were defined as IFN-γ spot forming cells ≥2 times the actin negative control. Spot forming cells (SFC) per 10 5 cells indicative of specific responses compared to actin stimulated cells: RESIST-001 (actin [17 SFC], nef [139 SFC]), RESIST-003 (actin [19 SFC], gag [659 SFC], pol [466 SFC], nef [1057 SFC], mos1 [540 SFC], mos2 [520 SFC]), RESIST-004 (actin [34 SFC], nef [117 SFC]), RESIST-005 (actin [65 SFC], nef [804 SFC]), RESIST-006 (actin [0 SFC], nef [236 SFC]), and RESIST-007 (actin [25 SFC], gag [1063 SFC], nef [854 SFC], mos1 [291 SFC], mos2 [290 SFC]). b Each bar reports the total sum (infusion 1 and infusion 2) of infused T cells specific for HIV Gag, Pol, and Nef epitopes for each HST-NEETs product ( n = 5). c Each bar reports the total sum (infusion 1 and infusion 2) of infused T cells specific for conserved epitopes in Gag/Pol Mosaic 1 and Mosaic 2 immunogens for each HST-NEETs product ( n = 5). d , e HST-NEET products ( n = 6) were predominantly <t>CD8+</t> effector memory T cells and had variable expression of T cell surface activation and exhaustion markers. f CD3+ CD8+ HST-NEET products ( n = 5) exhibited polyfunctional T cell responses upon stimulation with Gag, Pol, Nef and Gag/Pol Mos1 and Mos2 peptides as measured by intracellular production of IFN-γ and TNF-α. HIV-specific T cell activation was dominant in the CD8+ T cell fraction of all HST-NEET products. Source data are provided as a Source Data file.
    Cd8a Apc Vio770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8a+apc+vio770/CD8+Antibody%2C+anti-human%2C+REAfinity/pmc12081906-291-52-57
    Average 95 stars, based on 1 article reviews
    cd8a apc vio770 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    anti cd8a apc vio770  (Miltenyi Biotec)
    94
    Miltenyi Biotec anti cd8a apc vio770
    a HST-NEET products ( n = 6) exhibited variable antigen-specific IFN-γ responses against HIV Gag, Pol, Nef, and conserved epitope targets in the Gag/Pol Mos1 and Mos2 peptide mixes. RESIST-004 HST-NEET numbers after treatment-related studies were insufficient to test Gag/Pol Mos1 and Mos2 specificity. Positive ELISpot results were defined as IFN-γ spot forming cells ≥2 times the actin negative control. Spot forming cells (SFC) per 10 5 cells indicative of specific responses compared to actin stimulated cells: RESIST-001 (actin [17 SFC], nef [139 SFC]), RESIST-003 (actin [19 SFC], gag [659 SFC], pol [466 SFC], nef [1057 SFC], mos1 [540 SFC], mos2 [520 SFC]), RESIST-004 (actin [34 SFC], nef [117 SFC]), RESIST-005 (actin [65 SFC], nef [804 SFC]), RESIST-006 (actin [0 SFC], nef [236 SFC]), and RESIST-007 (actin [25 SFC], gag [1063 SFC], nef [854 SFC], mos1 [291 SFC], mos2 [290 SFC]). b Each bar reports the total sum (infusion 1 and infusion 2) of infused T cells specific for HIV Gag, Pol, and Nef epitopes for each HST-NEETs product ( n = 5). c Each bar reports the total sum (infusion 1 and infusion 2) of infused T cells specific for conserved epitopes in Gag/Pol Mosaic 1 and Mosaic 2 immunogens for each HST-NEETs product ( n = 5). d , e HST-NEET products ( n = 6) were predominantly <t>CD8+</t> effector memory T cells and had variable expression of T cell surface activation and exhaustion markers. f CD3+ CD8+ HST-NEET products ( n = 5) exhibited polyfunctional T cell responses upon stimulation with Gag, Pol, Nef and Gag/Pol Mos1 and Mos2 peptides as measured by intracellular production of IFN-γ and TNF-α. HIV-specific T cell activation was dominant in the CD8+ T cell fraction of all HST-NEET products. Source data are provided as a Source Data file.
    Anti Cd8a Apc Vio770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8a+apc+vio770/CD8a+Antibody%2C+anti-mouse%2C+APC-Vio+770%2C+REAfinity/pmc11805801-60-55-60
    Average 94 stars, based on 1 article reviews
    anti cd8a apc vio770 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    apc vio770 cd8a  (Miltenyi Biotec)
    95
    Miltenyi Biotec apc vio770 cd8a
    a HST-NEET products ( n = 6) exhibited variable antigen-specific IFN-γ responses against HIV Gag, Pol, Nef, and conserved epitope targets in the Gag/Pol Mos1 and Mos2 peptide mixes. RESIST-004 HST-NEET numbers after treatment-related studies were insufficient to test Gag/Pol Mos1 and Mos2 specificity. Positive ELISpot results were defined as IFN-γ spot forming cells ≥2 times the actin negative control. Spot forming cells (SFC) per 10 5 cells indicative of specific responses compared to actin stimulated cells: RESIST-001 (actin [17 SFC], nef [139 SFC]), RESIST-003 (actin [19 SFC], gag [659 SFC], pol [466 SFC], nef [1057 SFC], mos1 [540 SFC], mos2 [520 SFC]), RESIST-004 (actin [34 SFC], nef [117 SFC]), RESIST-005 (actin [65 SFC], nef [804 SFC]), RESIST-006 (actin [0 SFC], nef [236 SFC]), and RESIST-007 (actin [25 SFC], gag [1063 SFC], nef [854 SFC], mos1 [291 SFC], mos2 [290 SFC]). b Each bar reports the total sum (infusion 1 and infusion 2) of infused T cells specific for HIV Gag, Pol, and Nef epitopes for each HST-NEETs product ( n = 5). c Each bar reports the total sum (infusion 1 and infusion 2) of infused T cells specific for conserved epitopes in Gag/Pol Mosaic 1 and Mosaic 2 immunogens for each HST-NEETs product ( n = 5). d , e HST-NEET products ( n = 6) were predominantly <t>CD8+</t> effector memory T cells and had variable expression of T cell surface activation and exhaustion markers. f CD3+ CD8+ HST-NEET products ( n = 5) exhibited polyfunctional T cell responses upon stimulation with Gag, Pol, Nef and Gag/Pol Mos1 and Mos2 peptides as measured by intracellular production of IFN-γ and TNF-α. HIV-specific T cell activation was dominant in the CD8+ T cell fraction of all HST-NEET products. Source data are provided as a Source Data file.
    Apc Vio770 Cd8a, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8a+apc+vio770/CD8-APC-Vio770/pmc11730596-302-27-29
    Average 95 stars, based on 1 article reviews
    apc vio770 cd8a - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    anti rat cd8a apc vio770  (Miltenyi Biotec)
    93
    Miltenyi Biotec anti rat cd8a apc vio770
    a HST-NEET products ( n = 6) exhibited variable antigen-specific IFN-γ responses against HIV Gag, Pol, Nef, and conserved epitope targets in the Gag/Pol Mos1 and Mos2 peptide mixes. RESIST-004 HST-NEET numbers after treatment-related studies were insufficient to test Gag/Pol Mos1 and Mos2 specificity. Positive ELISpot results were defined as IFN-γ spot forming cells ≥2 times the actin negative control. Spot forming cells (SFC) per 10 5 cells indicative of specific responses compared to actin stimulated cells: RESIST-001 (actin [17 SFC], nef [139 SFC]), RESIST-003 (actin [19 SFC], gag [659 SFC], pol [466 SFC], nef [1057 SFC], mos1 [540 SFC], mos2 [520 SFC]), RESIST-004 (actin [34 SFC], nef [117 SFC]), RESIST-005 (actin [65 SFC], nef [804 SFC]), RESIST-006 (actin [0 SFC], nef [236 SFC]), and RESIST-007 (actin [25 SFC], gag [1063 SFC], nef [854 SFC], mos1 [291 SFC], mos2 [290 SFC]). b Each bar reports the total sum (infusion 1 and infusion 2) of infused T cells specific for HIV Gag, Pol, and Nef epitopes for each HST-NEETs product ( n = 5). c Each bar reports the total sum (infusion 1 and infusion 2) of infused T cells specific for conserved epitopes in Gag/Pol Mosaic 1 and Mosaic 2 immunogens for each HST-NEETs product ( n = 5). d , e HST-NEET products ( n = 6) were predominantly <t>CD8+</t> effector memory T cells and had variable expression of T cell surface activation and exhaustion markers. f CD3+ CD8+ HST-NEET products ( n = 5) exhibited polyfunctional T cell responses upon stimulation with Gag, Pol, Nef and Gag/Pol Mos1 and Mos2 peptides as measured by intracellular production of IFN-γ and TNF-α. HIV-specific T cell activation was dominant in the CD8+ T cell fraction of all HST-NEET products. Source data are provided as a Source Data file.
    Anti Rat Cd8a Apc Vio770, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8a+apc+vio770/CD8a+Antibody%2C+anti-rat%2C+APC-Vio+770%2C+REAfinity/pmc12535296-64-30-33
    Average 93 stars, based on 1 article reviews
    anti rat cd8a apc vio770 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    anti mouse cd8a apc vio770 miltenyi biotec  (Miltenyi Biotec)
    95
    Miltenyi Biotec anti mouse cd8a apc vio770 miltenyi biotec
    a HST-NEET products ( n = 6) exhibited variable antigen-specific IFN-γ responses against HIV Gag, Pol, Nef, and conserved epitope targets in the Gag/Pol Mos1 and Mos2 peptide mixes. RESIST-004 HST-NEET numbers after treatment-related studies were insufficient to test Gag/Pol Mos1 and Mos2 specificity. Positive ELISpot results were defined as IFN-γ spot forming cells ≥2 times the actin negative control. Spot forming cells (SFC) per 10 5 cells indicative of specific responses compared to actin stimulated cells: RESIST-001 (actin [17 SFC], nef [139 SFC]), RESIST-003 (actin [19 SFC], gag [659 SFC], pol [466 SFC], nef [1057 SFC], mos1 [540 SFC], mos2 [520 SFC]), RESIST-004 (actin [34 SFC], nef [117 SFC]), RESIST-005 (actin [65 SFC], nef [804 SFC]), RESIST-006 (actin [0 SFC], nef [236 SFC]), and RESIST-007 (actin [25 SFC], gag [1063 SFC], nef [854 SFC], mos1 [291 SFC], mos2 [290 SFC]). b Each bar reports the total sum (infusion 1 and infusion 2) of infused T cells specific for HIV Gag, Pol, and Nef epitopes for each HST-NEETs product ( n = 5). c Each bar reports the total sum (infusion 1 and infusion 2) of infused T cells specific for conserved epitopes in Gag/Pol Mosaic 1 and Mosaic 2 immunogens for each HST-NEETs product ( n = 5). d , e HST-NEET products ( n = 6) were predominantly <t>CD8+</t> effector memory T cells and had variable expression of T cell surface activation and exhaustion markers. f CD3+ CD8+ HST-NEET products ( n = 5) exhibited polyfunctional T cell responses upon stimulation with Gag, Pol, Nef and Gag/Pol Mos1 and Mos2 peptides as measured by intracellular production of IFN-γ and TNF-α. HIV-specific T cell activation was dominant in the CD8+ T cell fraction of all HST-NEET products. Source data are provided as a Source Data file.
    Anti Mouse Cd8a Apc Vio770 Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd8a+apc+vio770/CD8a+Antibody%2C+anti-mouse%2C+APC-Vio+770/pmc10897180__41467_2024_45984_MOESM3_ESM-45-100-103
    Average 95 stars, based on 1 article reviews
    anti mouse cd8a apc vio770 miltenyi biotec - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    a HST-NEET products ( n = 6) exhibited variable antigen-specific IFN-γ responses against HIV Gag, Pol, Nef, and conserved epitope targets in the Gag/Pol Mos1 and Mos2 peptide mixes. RESIST-004 HST-NEET numbers after treatment-related studies were insufficient to test Gag/Pol Mos1 and Mos2 specificity. Positive ELISpot results were defined as IFN-γ spot forming cells ≥2 times the actin negative control. Spot forming cells (SFC) per 10 5 cells indicative of specific responses compared to actin stimulated cells: RESIST-001 (actin [17 SFC], nef [139 SFC]), RESIST-003 (actin [19 SFC], gag [659 SFC], pol [466 SFC], nef [1057 SFC], mos1 [540 SFC], mos2 [520 SFC]), RESIST-004 (actin [34 SFC], nef [117 SFC]), RESIST-005 (actin [65 SFC], nef [804 SFC]), RESIST-006 (actin [0 SFC], nef [236 SFC]), and RESIST-007 (actin [25 SFC], gag [1063 SFC], nef [854 SFC], mos1 [291 SFC], mos2 [290 SFC]). b Each bar reports the total sum (infusion 1 and infusion 2) of infused T cells specific for HIV Gag, Pol, and Nef epitopes for each HST-NEETs product ( n = 5). c Each bar reports the total sum (infusion 1 and infusion 2) of infused T cells specific for conserved epitopes in Gag/Pol Mosaic 1 and Mosaic 2 immunogens for each HST-NEETs product ( n = 5). d , e HST-NEET products ( n = 6) were predominantly CD8+ effector memory T cells and had variable expression of T cell surface activation and exhaustion markers. f CD3+ CD8+ HST-NEET products ( n = 5) exhibited polyfunctional T cell responses upon stimulation with Gag, Pol, Nef and Gag/Pol Mos1 and Mos2 peptides as measured by intracellular production of IFN-γ and TNF-α. HIV-specific T cell activation was dominant in the CD8+ T cell fraction of all HST-NEET products. Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Autologous HIV-specific T cell therapy targeting conserved epitopes is well-tolerated in six adults with HIV: an open-label, single-arm phase 1 study

    doi: 10.1038/s41467-025-59810-2

    Figure Lengend Snippet: a HST-NEET products ( n = 6) exhibited variable antigen-specific IFN-γ responses against HIV Gag, Pol, Nef, and conserved epitope targets in the Gag/Pol Mos1 and Mos2 peptide mixes. RESIST-004 HST-NEET numbers after treatment-related studies were insufficient to test Gag/Pol Mos1 and Mos2 specificity. Positive ELISpot results were defined as IFN-γ spot forming cells ≥2 times the actin negative control. Spot forming cells (SFC) per 10 5 cells indicative of specific responses compared to actin stimulated cells: RESIST-001 (actin [17 SFC], nef [139 SFC]), RESIST-003 (actin [19 SFC], gag [659 SFC], pol [466 SFC], nef [1057 SFC], mos1 [540 SFC], mos2 [520 SFC]), RESIST-004 (actin [34 SFC], nef [117 SFC]), RESIST-005 (actin [65 SFC], nef [804 SFC]), RESIST-006 (actin [0 SFC], nef [236 SFC]), and RESIST-007 (actin [25 SFC], gag [1063 SFC], nef [854 SFC], mos1 [291 SFC], mos2 [290 SFC]). b Each bar reports the total sum (infusion 1 and infusion 2) of infused T cells specific for HIV Gag, Pol, and Nef epitopes for each HST-NEETs product ( n = 5). c Each bar reports the total sum (infusion 1 and infusion 2) of infused T cells specific for conserved epitopes in Gag/Pol Mosaic 1 and Mosaic 2 immunogens for each HST-NEETs product ( n = 5). d , e HST-NEET products ( n = 6) were predominantly CD8+ effector memory T cells and had variable expression of T cell surface activation and exhaustion markers. f CD3+ CD8+ HST-NEET products ( n = 5) exhibited polyfunctional T cell responses upon stimulation with Gag, Pol, Nef and Gag/Pol Mos1 and Mos2 peptides as measured by intracellular production of IFN-γ and TNF-α. HIV-specific T cell activation was dominant in the CD8+ T cell fraction of all HST-NEET products. Source data are provided as a Source Data file.

    Article Snippet: Antibodies used in panels for cell surface staining differed between the GMP and non-GMP laboratories, and were combinations of the following: CD3 PE-Cy7 (Cat: 317334, Biolegend), CD3 PerCP-Vio700 (Cat: 130-113-141, Miltenyi), CD3 BV785 (Cat: 317330, Biolegend), CD4 BV605 (Cat: 317438, Biolegend), CD4 PE Vio770 (Cat: 130-113-227, Miltenyi), CD8a BV421 (Cat: 301036, Biolegend), CD8a APC Vio770 (Cat: 130-110-681, Miltenyi), CCR7 Alexa Fluor 700 (Cat: 353244, Biolegend), CCR7 FITC (Cat: 130-120-468, Miltenyi), CD45RO PE-Dazzle 594 (Cat: 304248, Biolegend), CD45RO PE (Cat: 130-113-559, Miltenyi), CD19 FITC (Cat: 130-113-645, Miltenyi), CD14 VioBlue (Cat: 130-110-524, Miltenyi), CD16 PE (Cat: 130-113-393, Miltenyi), CD56 BV650 (Cat: 318344, Biolegend), CD56 PE (Cat: 130-113-312, Miltenyi), TCRγδ APC-Fire 750 (Cat: 331228, Biolegend), TCRγδ (Cat: 130-113-512, Miltenyi), TCRαβ PerCP/Cyanine5.5 (Cat: 306724, Biolegend), TCRαβ FITC (Cat: 130-113-538, Miltenyi), CD160 PE-Cy7 (Cat: 341212, Biolegend), CTLA4 PE-Dazzle 594 (Cat: 369616, Biolegend), LAG3 PE (Cat: 369306, Biolegend), PD-1 FITC (Cat: 329904, Biolegend), TIM3 BV650 (Cat: 345028, Biolegend), CD107a PE-Cy7 (Cat: 328618, Biolegend), CD45 APC (Cat: 130-110-633, Miltenyi), CD83 PE (Cat: 130-110-503, Miltenyi), CD62 VioBlue (Cat: 130-113-622, Miltenyi), HLA-DR FITC (Cat: 30-111-788, Miltenyi), and CD95 APC (Cat: 558814, BD Biosciences).

    Techniques: Enzyme-linked Immunospot, Negative Control, Expressing, Activation Assay

    a Comprehensive pooled peptide epitope mapping of HST-NEETs revealed 15-mer peptides driving HIV-specific responses in each product ( n = 5). RESIST-001, -003, -005, and -006 ELISpots were conducted as singlets based on HST-NEET numbers available for characterization studies, and RESIST-007 ELISpots were conducted in duplicate. Plotted SFC per 10 5 cells is shown above each bar. b – f HST-NEET products were stimulated with 15-mer peptides in ( a ) for 5 h and intracellular production of IFN-γ and TNF-α in CD8+ T cells was evaluated to confirm epitope-specific responses. Peptides evaluated are named by the first two amino acids in the 15-mer sequence followed by the peptide length. g Minimal (9 amino acid) epitopes associated with CD8+ T cell responses were determined for each product. RESIST-004 HST-NEETs were unavailable for these product characterization studies. Positive ELISpot results were defined as IFN-γ spot forming cells ≥2 times the actin negative control. RESIST-005 ELISpots were conducted as singlets, RESIST-001, -003, -006, and -007 were conducted in duplicate. Plotted SFC per 10 5 cells is shown above each bar.

    Journal: Nature Communications

    Article Title: Autologous HIV-specific T cell therapy targeting conserved epitopes is well-tolerated in six adults with HIV: an open-label, single-arm phase 1 study

    doi: 10.1038/s41467-025-59810-2

    Figure Lengend Snippet: a Comprehensive pooled peptide epitope mapping of HST-NEETs revealed 15-mer peptides driving HIV-specific responses in each product ( n = 5). RESIST-001, -003, -005, and -006 ELISpots were conducted as singlets based on HST-NEET numbers available for characterization studies, and RESIST-007 ELISpots were conducted in duplicate. Plotted SFC per 10 5 cells is shown above each bar. b – f HST-NEET products were stimulated with 15-mer peptides in ( a ) for 5 h and intracellular production of IFN-γ and TNF-α in CD8+ T cells was evaluated to confirm epitope-specific responses. Peptides evaluated are named by the first two amino acids in the 15-mer sequence followed by the peptide length. g Minimal (9 amino acid) epitopes associated with CD8+ T cell responses were determined for each product. RESIST-004 HST-NEETs were unavailable for these product characterization studies. Positive ELISpot results were defined as IFN-γ spot forming cells ≥2 times the actin negative control. RESIST-005 ELISpots were conducted as singlets, RESIST-001, -003, -006, and -007 were conducted in duplicate. Plotted SFC per 10 5 cells is shown above each bar.

    Article Snippet: Antibodies used in panels for cell surface staining differed between the GMP and non-GMP laboratories, and were combinations of the following: CD3 PE-Cy7 (Cat: 317334, Biolegend), CD3 PerCP-Vio700 (Cat: 130-113-141, Miltenyi), CD3 BV785 (Cat: 317330, Biolegend), CD4 BV605 (Cat: 317438, Biolegend), CD4 PE Vio770 (Cat: 130-113-227, Miltenyi), CD8a BV421 (Cat: 301036, Biolegend), CD8a APC Vio770 (Cat: 130-110-681, Miltenyi), CCR7 Alexa Fluor 700 (Cat: 353244, Biolegend), CCR7 FITC (Cat: 130-120-468, Miltenyi), CD45RO PE-Dazzle 594 (Cat: 304248, Biolegend), CD45RO PE (Cat: 130-113-559, Miltenyi), CD19 FITC (Cat: 130-113-645, Miltenyi), CD14 VioBlue (Cat: 130-110-524, Miltenyi), CD16 PE (Cat: 130-113-393, Miltenyi), CD56 BV650 (Cat: 318344, Biolegend), CD56 PE (Cat: 130-113-312, Miltenyi), TCRγδ APC-Fire 750 (Cat: 331228, Biolegend), TCRγδ (Cat: 130-113-512, Miltenyi), TCRαβ PerCP/Cyanine5.5 (Cat: 306724, Biolegend), TCRαβ FITC (Cat: 130-113-538, Miltenyi), CD160 PE-Cy7 (Cat: 341212, Biolegend), CTLA4 PE-Dazzle 594 (Cat: 369616, Biolegend), LAG3 PE (Cat: 369306, Biolegend), PD-1 FITC (Cat: 329904, Biolegend), TIM3 BV650 (Cat: 345028, Biolegend), CD107a PE-Cy7 (Cat: 328618, Biolegend), CD45 APC (Cat: 130-110-633, Miltenyi), CD83 PE (Cat: 130-110-503, Miltenyi), CD62 VioBlue (Cat: 130-113-622, Miltenyi), HLA-DR FITC (Cat: 30-111-788, Miltenyi), and CD95 APC (Cat: 558814, BD Biosciences).

    Techniques: Sequencing, Enzyme-linked Immunospot, Negative Control